Coherus Biosciences | CHRS - Koszty Operacyjne





Koszty Operacyjne Zmiana Data
AbbVie USD 10.27B 538M 2026-03
Acadia Pharmaceuticals USD 272.68M 6.08M 2026-03
Akebia Therapeutics USD 63.08M 8.26M 2025-12
ALKERMES USD 1.75B 1.43B 2026-03
Alnylam Pharmaceuticals USD 898.54M 66.78M 2026-03
Amarin USD 51.48M 113K 2025-12
Amgen USD 4.78B 1.12B 2026-03
Baxter International USD 6.04B 2.85B 2026-03
Biogen USD 1.96B 69.6M 2026-03
BioMarin Pharmaceutical USD 636.56M 39.61M 2026-03
Bristol-Myers Squibb USD 20.07B 11.77B 2026-03
Coherus Biosciences USD 51.83M 2.48M 2025-12
Eli Lilly USD 10.02B 285M 2026-03
Fujifilm JPY 825.49B 58.1B 2026-03
Gilead Sciences USD 23.52B 18.55B 2026-03
Ironwood Pharmaceuticals USD 57.33M 8.63M 2024-12
Merck USD 18.17B 8.01B 2026-03
Myriad Genetics USD 212.8M 16.2M 2025-12
Pacira USD 172.75M 20.93M 2026-03
Perrigo USD 935.6M 89.6M 2026-03
Pfizer USD 90.1B 77.19B 2026-03
PTC Therapeutics USD 226.66M 19.64M 2026-03
Regeneron Pharmaceuticals USD 31.42B 28.44B 2026-03
Sarepta Therapeutics USD 372.37M 480.65M 2026-03
Teva Pharmaceutical Industries USD 3.22B 1000M 2026-03
Vertex Pharmaceuticals USD 1.85B 78.6M 2026-03
Xencor USD 82.38M 513K 2026-03
Zoetis USD 3.23B 1.68B 2026-03